Opexa licenses and maintains a variety of patents covering the treatment of autoimmune diseases, including MS. In the past year alone, Opexa has received eight patents or notices of allowance for related inventions, including a key patent recently issued by the European patent office. The European patent is the fiftieth (50th) patent awarded worldwide under Opexa's direction for its proprietary T-cell platform and validates Opexa as a leader in the field of Precision ImmunotherapyTM. Opexa has a broad patent portfolio protecting its technology in
European patent no. 2335720 was recently granted and is valid in 18 European countries. The European patent covers the manufacture of patient-specific T-cell vaccines created using immunogenic fragments of myelin proteins. It further protects the use of Tcelna as a treatment for MS. Tcelna, Opexa's leading pharmaceutical candidate, is a personalized T-cell immunotherapy currently in a Phase IIb clinical development program for the treatment of Secondary Progressive MS (SPMS). Tcelna has been granted Fast Track Designation from the
Additional patents that have recently been granted include European patent no. 1677821, which is directed toward a T-cell vaccine enriched in CD8+ T-cells for treating MS, and Israeli patent no. 195115, granted for personalized T-cell vaccines comprising T-cells specific to the most immunogenic epitopes of any autoantigen. A notice of allowance was received last month with respect to U.S. patent application no. 12/306,894, directed toward the use of a personalized T-cell vaccine for the treatment of rheumatoid arthritis.
"As a leader in the novel field of Precision Immunotherapy, it is vital that we build and protect our intellectual property position globally. This serves to maintain our competitive advantage and also enables us to build incremental shareholder value," stated
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.
Most Popular Stories
- Hezbollah Chief's Assassination Claimed by Sunni Group
- U.S. Growth Stayed Steady During Shutdown, Fed Says
- Allstate Seeks to Invest in Minority Firms
- Newtown Massacre Heard on 911 Recordings
- SpaceX's Satellite Launch Is 'Game-Changer'
- Latin Music Conference Turns 25
- Climate Change Early Warning System Urged
- Guardian Pressured to Stop NSA Stories: Editor
- New Home Sales Shoot up 25 Percent in October
- Reid Confident Congress to Pass Immigration Bill